ATAIBeckley Inc Share Price Today: Live Updates & Key Insights

ATAIBeckley Inc share price today is $7.15, up 0.14%. The stock opened at $7.17 against the previous close of $7.17, with an intraday high of $7.19 and low of $7.165.

ATAIBeckley Inc Share Price Chart

ATAIBeckley Inc

us-stock
To Invest in {{usstockname}}
us-stock

ATAIBeckley Inc Share Price Performance

$7.15 0.0014(0.14%) ATAI at 27 Jul 2026 02:02 PM Biotechnology
Lowest Today 7.165
Highest Today 7.19
Today’s Open 7.17
Prev. Close 7.17
52 Week High 7.22
52 Week Low 3.06
Day’s Range: Low 7.165 High 7.19
52-Week Range: Low 3.06 High 7.22
1 day return -
1 Week return -0.2
1 month return +36.01
3 month return +65.7
6 month return +83.5
1 year return +116.11
3 year return +250.0
5 year return -55.79
10 year return -

ATAIBeckley Inc Institutional Holdings

Deep Track Capital, LP 3.26

Vanguard Capital Management, LLC 3.19

Vanguard Total Stock Mkt Idx Inv 2.50

iShares Russell 2000 ETF 2.26

UBS Group AG 2.02

BlackRock Inc 1.86

Adage Capital Partners Gp LLC 1.53

Susquehanna International Group, LLP 1.44

Millennium Management LLC 1.19

ARK Genomic Revolution ETF 1.18

ARK Genomic Revolution 1.12

Morgan Stanley - Brokerage Accounts 1.05

Candriam Luxembourg S.C.A. 0.84

Qube Research & Technologies 0.79

Foresite Capital Management VI LLC 0.75

iShares Russell 2000 Growth ETF 0.71

Geode Capital Management, LLC 0.68

Marshall Wace Asset Management Ltd 0.64

Vanguard Institutional Extnd Mkt Idx Tr 0.61

Candriam Eqs L Biotech C USD Cap 0.58

iShares Biotechnology ETF 0.57

RTW INVESTMENTS, LLC 0.54

Two Sigma Investments LLC 0.54

Vanguard Russell 2000 ETF 0.50

Newtyn Management LLC 0.48

State Street® SPDR® S&P® PhrmctlsETF 0.47

Eagle Health Investments LP 0.46

State St Russell Sm/Mid Cp® Indx SL Cl I 0.46

HBM Healthcare Investments AG Ord 0.41

Vanguard Fiduciary Trust Co 0.34

State St Russell Sm Cap® Idx SL Cl I 0.32

Charles Schwab Investment Management Inc 0.32

State Street Corp 0.31

First Trust Small Cap Gr AlphaDEX® ETF 0.29

Fidelity Extended Market Index 0.27

Schwab US Small-Cap ETF™ 0.25

AdvisorShares Psychedelics ETF 0.24

T. Rowe Price Integrated US SmCapGrEq 0.24

Morgan Stanley Inception 0.22

Morgan Stanley Inst Inception I 0.22

ATAIBeckley Inc Market Status

Strong Buy: 5

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

ATAIBeckley Inc Fundamentals

Market Cap 2652.57 M

PB Ratio 13.3694

PE Ratio 0.0

Enterprise Value 2427.51 M

Total Assets 310.54 M

Volume 6965932

ATAIBeckley Inc Company Financials

Annual Revenue FY23:334000 0.3M, FY22:233000 0.2M, FY21:20376000 20.4M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:233000 0.2M, FY21:20376000 20.4M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-66943000 -66.9M, FY22:-141411000 -141.4M, FY21:-132612000 -132.6M, FY20:-102118000 -102.1M, FY19:-17476000 -17.5M

Quarterly Revenue Q1/2026:953999 1.0M, Q3/2025:749000 0.7M, Q2/2025:719000 0.7M, Q1/2025:1555000 1.6M, Q3/2024:40000 0.0M

Quarterly Profit Q1/2026:787000 0.8M, Q3/2025:749000 0.7M, Q2/2025:719000 0.7M, Q1/2025:-9283000 -9.3M, Q3/2024:40000 0.0M

Quarterly Net worth Q1/2026:-29781999 -29.8M, Q3/2025:-61074000 -61.1M, Q2/2025:-27729000 -27.7M, Q1/2025:-26431000 -26.4M, Q3/2024:-26286000 -26.3M

About ATAIBeckley Inc & investment objective

Company Information AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. The company was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York.

Organisation Biotechnology

Employees 99

Industry Biotechnology

CEO Dr. Srinivas G. Rao M.D., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

ATAIBeckley Inc FAQs

What is the share price of ATAIBeckley Inc today?

The current share price of ATAIBeckley Inc is $7.15.

Can I buy ATAIBeckley Inc shares in India?

Yes, Indian investors can buy ATAIBeckley Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy ATAIBeckley Inc shares in India?

You can easily invest in ATAIBeckley Inc shares from India by:

Can I buy fractional shares of ATAIBeckley Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of ATAIBeckley Inc?

ATAIBeckley Inc has a market cap of $2652.57 M.

In which sector does ATAIBeckley Inc belong?

ATAIBeckley Inc operates in the Biotechnology sector.

What documents are required to invest in ATAIBeckley Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of ATAIBeckley Inc?

The PE ratio of ATAIBeckley Inc is N/A and the PB ratio is 13.37.